The MY-PROMPT-2 trial was funded in the MRFF 'Rare cancers, rare diseases and unmet needs' grant opportunity from last year. Grant success was confirmed early in January.
Treatment of multiple myeloma (MM) is now very complex and costly. However, survival benefits achieved with new therapies in clinical trials are not being seen in clinical practice, in part because many MM patients stop therapy early, often due to side-effects. The MY-PROMPT-2 trial tests whether real-time symptom feedback using patient-reported outcome measures improves duration on treatment, leading to better patient outcomes and more efficient use of these high-cost medicines.